Fact CheckerSign in

NCT06899399Recruiting

Efficacy and Safety Study of Endovascular Treatment of Asymptomatic Carotid Artery Stenosis

Source: ClinicalTrials.gov · Last updated 28 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial designed to evaluate the safety and efficacy of endovascular stenting combined with optimal medical therapy versus optimal medical therapy alone in patients with asymptomatic severe stenosis (70-99%) of the internal carotid artery. The study plans to enroll 982 patients aged 40-80 years who have had no ipsilateral carotid artery-related neurological symptoms in the past six months and who have declined carotid endarterectomy. The primary endpoints include stroke, myocardial infarction, or death within 30 days post-procedure/enrollment, as well as the incidence of ipsilateral stroke from 30 days to one year post-procedure/enrollment. Secondary endpoints include procedural success rate, restenosis rate, changes in cognitive function, and others. The study results will provide high-level evidence-based medical evidence for the treatment selection of patients with asymptomatic carotid artery stenosis.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
982 (estimated)
First submitted
21 Mar 2025
Start date
18 Oct 2024
Primary completion date
Jul 2028
Lead sponsor
Beijing Tiantan Hospital
Diseases
Stroke
NCT number
NCT06899399

What you commit to

  • Study type: Interventional
  • Planned participants: 982
  • From 18 Oct 2024 to the primary completion date, Jul 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients with larger intracranial aneurysms (diameter \>5 mm) who cannot undergo prior or concurrent treatment
  • The patient does not attend the clinical trial of other drug or medical device before enrollment

Other illness

  • Spontaneous intracranial hemorrhage in nearly one year
  • Patients with transient or permanent neurological deficit resulting from Neurological deficits mimicking TIA/stroke from TIA or stroke
  • Patients with severe dementia
  • Myocardial infarction within 30 days
  • Cardiogenic embolism, including left ventricular aneurysm, intraluminal filling defects, cardiomyopathy, aortic or mitral valve-prosthetic heart valve, calcified aortic stenosis, infective endocarditis
  • Contrast allergy

Lab values

  • Ejection fraction \<30% or New York Heart Association (NYHA) functional class III or higher; unstable angina, characterized by angina at rest with electrocardiogram changes
  • Platelets \<5 \* 104 / uL, INR\> 1.5, bleeding time\> 1min or heparin-related thrombocytopenia; heparin is a contraindication to antiplatelet drugs; coagulopathy
  • Poor controlled diabetes mellitus, fasting blood glucose\> 22 mmol/L and ketone body\>+2
  • Severe liver and kidney function impairment, ALT\> 3 times the upper limit of normal value or AST\> 3 times the upper limit of normal value, blood creatinine increase\> 2 times the upper limit of normal value

Age

  • Malignant tumor or respiratory insufficiency, and a life expectancy of \<5 years
  • The stenotic lesion exhibits severe circumferential calcification, defined as calcification greater than 3 mm in thickness visible in orthogonal views during fluoroscopy. (Note: In elderly subjects aged ≥70 years, anatomical factors such as tortuosity, arch anatomy, and calcification must be assessed more carefully)

Other

  • symptomatic internal carotid artery stenosis in the past 6 months
  • Chronic occlusion without obvious symptoms of cerebral ischemic attack
  • Common carotid artery ostial lesion
  • Tandem lesions with severe stenosis of the ipsilateral intracranial artery
  • Internal carotid artery dissection
  • Internal carotid artery aneurysm
  • Mitral stenosis, atrial septal defect, atrial septal aneurysm or left chamber myxoma
  • Two or more proximal or main coronary artery stenosis 70%, untreated or recanable
  • Other general anesthesia operations are required during the same period
  • Pregnant or lactating women
  • The investigator is not considered fit to participate in this clinical study
    • Imaging exclusion criteria:
  • Type III aortic arch
  • Severe angulation or tortuosity (≥90 degrees) of the common carotid artery or innominate artery that prevents safe and rapid placement of a guiding catheter or long sheath
  • Severe angulation or tortuosity of the internal carotid artery that prevents safe deployment of an embolic protection device or stent. Severe tortuosity is defined as the presence of two or more angles ≥90 degrees within 4 cm of the stenotic lesion
  • Stenosis of the beginning or proximal end of the common carotid artery, innominate artery, distal or intracranial segment of the internal carotid artery, and the stenosis degree is greater than that of the target stenosis

Who the study is looking for

  • Age 40-80 years
  • Severe asymptomatic internal carotid artery stenosis (70-99%) confirmed by ultrasound/CTA/DSA
  • Contralateral ICA stenosis \<70%
  • No TIA/stroke related to target lesion in past 6 months
  • Declined carotid endarterectomy
  • Willing to complete 12-month follow-up
  • Signed informed consent by participant/legal representative

Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Beijing Tiantan Hospital,Capital Medical University
Coordinator of this site? Confirm its status
BeijingChinaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.